{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T23:11:27Z","timestamp":1767136287144,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd012169","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,10,2]],"date-time":"2017-10-02T00:00:00Z","timestamp":1506902400000}}],"reference-count":101,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012169.pub2","type":"journal-article","created":{"date-parts":[[2017,10,2]],"date-time":"2017-10-02T16:51:08Z","timestamp":1506963068000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome"],"prefix":"10.1002","author":[{"given":"Malgorzata M","family":"Bala","sequence":"first","affiliation":[{"name":"Jagiellonian University Medical College; Chair of Epidemiology and Preventive Medicine; Department of Hygiene and Dietetics; Systematic Reviews Unit; Kopernika 7 Krakow Poland 31-034"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Celinska-Lowenhoff","sequence":"additional","affiliation":[{"name":"Jagiellonian University Medical College; 2nd Department of Internal Medicine, Department of Allergy and Immunology; Skawinska 8 Krakow Poland 31-066"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech","family":"Szot","sequence":"additional","affiliation":[{"name":"Jagiellonian University Medical College; Department of Hygiene and Dietetics; Krakow Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Padjas","sequence":"additional","affiliation":[{"name":"Jagiellonian University Medical College; 2nd Department of Internal Medicine, Department of Allergy and Immunology; Skawinska 8 Krakow Poland 31-066"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mateusz","family":"Kaczmarczyk","sequence":"additional","affiliation":[{"name":"Jagiellonian University Medical College; Systematic Reviews Unit - Polish Cochrane Branch; Krakow Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mateusz J","family":"Swierz","sequence":"additional","affiliation":[{"name":"Jagiellonian University Medical College; Department of Hygiene and Dietetics, Systematic Reviews Unit; Krakow Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anetta","family":"Undas","sequence":"additional","affiliation":[{"name":"Jagiellonian University Medical College; Institute of Cardiology; Pradnicka 80 Krakow Poland 31-202"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,10,2]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD012169.pub2-BIB0001|cit1","first-page":"148a","article-title":"A randomized trial of two intensities of warfarin (international normalized ratio of 2.0 to 3.0 versus 3.1 to 4.0) for the prevention of recurrent thrombosis in patients with antiphospholipid antibodies","volume":"100","author":"Crowther","year":"2002","journal-title":"Blood"},{"issue":"12","key":"10.1002\/14651858.CD012169.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1056\/NEJMoa035241","article-title":"A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome","volume":"349","author":"Crowther","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012169.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.7150\/ijms.7.15","article-title":"Comparison between single antiplatelet therapy and combination of anti-platelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome","volume":"7","author":"Okuma","year":"2010","journal-title":"International Journal of Medical Sciences"},{"key":"10.1002\/14651858.CD012169.pub2-BIB0004|cit4","unstructured":"Okuma H lijima K Goto Y Yasuda T Tokuoka K Kitagawa Y Prevention in ischemic stroke with antiphospholipid syndrome Proceedings of the International Stroke Conference 2013. 6-8 February 2013; Honolulu, Hawaii, USA 2013"},{"key":"10.1002\/14651858.CD012169.pub2-BIB0005|cit5","unstructured":"2012-002345-38 A prospective randomised controlled phase II\/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-002345-38\/GB\/"},{"issue":"S2","key":"10.1002\/14651858.CD012169.pub2-BIB0006|cit6","first-page":"281","article-title":"Rivaroxaban limits complement activation in patients with thrombotic antiphospholipid syndrome","volume":"13","author":"Arachchillage","year":"2015","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"23","key":"10.1002\/14651858.CD012169.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1182\/blood.V126.23.2328.2328","article-title":"Rivaroxaban limits complement activation compared to warfarin in antiphospholipid syndrome patients with venous thromboembolism","volume":"126","author":"Arachchillage","year":"2015","journal-title":"Blood"},{"issue":"11","key":"10.1002\/14651858.CD012169.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1111\/jth.13475","article-title":"Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism","volume":"14","author":"Arachchillage","year":"2016","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"s2","key":"10.1002\/14651858.CD012169.pub2-BIB0009|cit9","first-page":"860","article-title":"A prospective randomised controlled phase II\/III clinical trial of rivaroxaban vs. warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE","volume":"11","author":"Cohen","year":"2013","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"10","key":"10.1002\/14651858.CD012169.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1177\/0961203315581207","article-title":"Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II\/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE","volume":"24","author":"Cohen","year":"2015","journal-title":"Lupus"},{"issue":"S2","key":"10.1002\/14651858.CD012169.pub2-BIB0011|cit11","first-page":"84","article-title":"A prospective randomised controlled phase II\/III clinical trial of rivaroxaban vs. warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE","volume":"13","author":"Cohen","year":"2015","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"9","key":"10.1002\/14651858.CD012169.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"e426-36","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2\/3, non-inferiority trial","volume":"3","author":"Cohen","year":"2016","journal-title":"Lancet Haematology"},{"key":"10.1002\/14651858.CD012169.pub2-BIB0013|cit13","unstructured":"ISRCTN68222801 A prospective randomised controlled phase II\/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS) https:\/\/www.isrctn.com\/ISRCTN68222801"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012169.pub2-BIB0014|cit14","first-page":"38","article-title":"Feasibility of a randomized clinical trial for the prevention of recurrent thrombosis in the antiphospholipid syndrome","volume":"147","author":"Finazzi","year":"1996","journal-title":"Annales de Medecine Interne"},{"issue":"S2","key":"10.1002\/14651858.CD012169.pub2-BIB0015|cit15","first-page":"315","article-title":"Proposal of an international clinical trial of high-dose warfarin in the antiphospholipid syndrome (APS)","volume":"93","author":"Finazzi","year":"1996","journal-title":"British Journal of Haematology"},{"issue":"5","key":"10.1002\/14651858.CD012169.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1538-7836.2005.01340.x","article-title":"A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)","volume":"3","author":"Finazzi","year":"2005","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012169.pub2-BIB0020|cit17","first-page":"135","article-title":"The WAPS (warfarin in antiphospholipid syndrome) study. Update and preliminary results","volume":"1","author":"Finazzi","year":"2000","journal-title":"Hematology Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012169.pub2-BIB0017|cit18","first-page":"OC365","article-title":"A randomized clinical trial of oral anticoagulant therapy in patients with the antiphospholipid syndrome: the WAPS study [abstract]","volume":"1","author":"Finazzi","year":"2003","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"11 Part 1","key":"10.1002\/14651858.CD012169.pub2-BIB0018|cit19","first-page":"16a","article-title":"A randomized clinical trial of two intensities of oral anticoagulant therapy in patients with the antiphospholipid syndrome: final results of the WAPS","volume":"102","author":"Finazzi","year":"2003","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012169.pub2-BIB0019|cit20","first-page":"350","article-title":"The WAPS trial (warfarin in the antiphospholipid syndrome): study population and preliminary results","volume":"1","author":"Finazzi","year":"2002","journal-title":"Hematology Journal"},{"key":"10.1002\/14651858.CD012169.pub2-BIB0021|cit21","unstructured":"Triplett D (as supplied by Cochrane Stroke Group 17 January 2017) Warfarin for the prevention of recurrent thrombosis in the AntiPhospholipid Syndrome Data on file"},{"issue":"4","key":"10.1002\/14651858.CD012169.pub2-BIB0024|cit22","first-page":"541","article-title":"Plasma levels of platelet-derived microparticle (PDMP) may be an useful indicator of antiplatelet therapy in antiphospholipid syndrome (APS)","volume":"19","author":"Yamazaki","year":"2010","journal-title":"Lupus"},{"issue":"Suppl. 2","key":"10.1002\/14651858.CD012169.pub2-BIB0022|cit23","first-page":"720","article-title":"Combined antiplatelet agents might help prevent arterial thromboses in antiphospholipid syndrome","volume":"7","author":"Yamazaki","year":"2009","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"Suppl. 2","key":"10.1002\/14651858.CD012169.pub2-BIB0023|cit24","first-page":"951","article-title":"Plasma levels of platelet-derived microparticles (PDMP) might comprise a useful indicator for antiplatelet therapy in antiphospholipid syndrome (APS)","volume":"7","author":"Yamazaki","year":"2009","journal-title":"Thrombosis and Haemostasis"},{"issue":"s10","key":"10.1002\/14651858.CD012169.pub2-BIB0025|cit25","first-page":"1285","article-title":"Primary prevention of thrombosis in antiphospholipid antibodies positive patients: a prospective, multicenter, randomised, open trial comparing low dose aspirin with low dose aspirin plus low intensity oral anticoagulation","volume":"60","author":"Cuadrado","year":"2009","journal-title":"Arthritis & Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD012169.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/rheumatology\/ket313","article-title":"Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS)","volume":"53","author":"Cuadrado","year":"2014","journal-title":"Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD012169.pub2-BIB0027|cit27","first-page":"544","article-title":"The use of warfarin and low-dose aspirin in patients with antiphospholipid syndrome","volume":"19","author":"Kondratyeva","year":"2010","journal-title":"Lupus"},{"issue":"5","key":"10.1002\/14651858.CD012169.pub2-BIB0028|cit28","first-page":"33","article-title":"Recurrences of thromboses and hemorrhagic complications in patients with antiphospholipid syndrome during therapy with warfarin plus aspirin","volume":"82","author":"Kondratyeva","year":"2010","journal-title":"Terapevticheskii Arkhiv"},{"issue":"5","key":"10.1002\/14651858.CD012169.pub2-BIB0029|cit29","first-page":"47","article-title":"Warfarin in the treatment of antiphospholipid syndrome","volume":"79","author":"Reshetnyak","year":"2007","journal-title":"Terapevticheskii Arkhiv"},{"issue":"S3","key":"10.1002\/14651858.CD012169.pub2-BIB0030|cit30","first-page":"282","article-title":"Preventive stroke strategies antiphospholipid syndrome in ischemic stroke patients","volume":"9","author":"Okuma","year":"2014","journal-title":"International Journal of Stroke"},{"issue":"11","key":"10.1002\/14651858.CD012169.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1182\/blood.V110.11.4002.4002","article-title":"Combined antithrombotic therapy but not single-agent therapy with low-dose aspirin deteriorated platelet activation in patients with antiphospholipid syndrome (APS)","volume":"110","author":"Yamazaki","year":"2007","journal-title":"Blood"},{"key":"10.1002\/14651858.CD012169.pub2-BIB0032|cit32","unstructured":"2010-019764-36 Rivaroxaban vs acenocumarol in secondary prophylaxis of antiphospholipid syndrome: multicenter, randomized, prospective study. www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-019764-36\/ES"},{"key":"10.1002\/14651858.CD012169.pub2-BIB0033|cit33","unstructured":"NCT02295475 Apixaban for the secondary prevention of thromboembolism: a prospective randomized outcome pilot study among patients with the AntiphosPholipid Syndrome clinicaltrials.gov\/show\/NCT02295475"},{"issue":"3","key":"10.1002\/14651858.CD012169.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/1076029615615960","article-title":"Apixaban for the secondary prevention of thrombosis among patients with Antiphospholipid Syndrome: study rationale and design (ASTRO-APS)","volume":"22","author":"Woller","year":"2016","journal-title":"Clinical and Applied Thrombosis\/Hemostasis"},{"key":"10.1002\/14651858.CD012169.pub2-BIB0035|cit35","unstructured":"C000000342 Japan Antiphospholipid syndrome-Stroke Prevention Study upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000000395"},{"key":"10.1002\/14651858.CD012169.pub2-BIB0036|cit36","unstructured":"NCT02926170 Rivaroxaban versus acenocumarol for secondary thromboprophylaxis in patients with Antiphospholipid Syndrome: a randomized, prospective, phase III study. Analysis of stratification prognostic factors clinicaltrials.gov\/show\/NCT02926170"},{"key":"10.1002\/14651858.CD012169.pub2-BIB0037|cit37","unstructured":"2013-004575-13 A prospective, randomized clinical trial comparing rivaroxaban vs warfarin in high risk patients with Antiphospholipid Syndrome (TRAPS) www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-004575-13\/IT"},{"key":"10.1002\/14651858.CD012169.pub2-BIB0038|cit38","unstructured":"NCT02157272 A prospective, randomized clinical trial comparing rivaroxaban vs warfarin in high risk patients with Antiphospholipid Syndrome clinicaltrials.gov\/show\/NCT02157272"},{"issue":"3","key":"10.1002\/14651858.CD012169.pub2-BIB0039|cit39","first-page":"301","article-title":"Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial","volume":"25","author":"Pengo","year":"2016","journal-title":"Lupus 2016"},{"issue":"5","key":"10.1002\/14651858.CD012169.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1161\/01.STR.6.5.564","article-title":"Classification and outline of cerebrovascular diseases II","volume":"6","author":"Advisory Council for the National Institute of Neurological and Communicative Disorders and Stroke II","year":"1975","journal-title":"Stroke"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD012169.pub2-BIB0041|cit41","first-page":"e44S-e88S","article-title":"Oral anticoagulant therapy, antithrombotic therapy and prevention of thrombosis, 9th edition. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Ageno","year":"2012","journal-title":"Chest"},{"issue":"2","key":"10.1002\/14651858.CD012169.pub2-BIB0042|cit42","first-page":"141","article-title":"Antiocoagulation for the secondary prevention of ischemic stroke","volume":"62","author":"Alegria","year":"2010","journal-title":"Revista de Investigaci\u00f3n Cl\u00ednica"},{"issue":"11","key":"10.1002\/14651858.CD012169.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1002\/acr.22066","article-title":"Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature","volume":"65","author":"Andreoli","year":"2013","journal-title":"Arthritis Care & Research"},{"issue":"2","key":"10.1002\/14651858.CD012169.pub2-BIB0044|cit44","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012534","article-title":"Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies","author":"Bala","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD012169.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"3067-78","DOI":"10.1161\/01.STR.31.12.3067","article-title":"Diagnostic testing for coagulopathies in patients with ischemic stroke","volume":"31","author":"Bushnell","year":"2000","journal-title":"Stroke"},{"issue":"4","key":"10.1002\/14651858.CD012169.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/art.10187","article-title":"Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients","volume":"46","author":"Cervera","year":"2002","journal-title":"Arthritis and Rheumatism"},{"issue":"9","key":"10.1002\/14651858.CD012169.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1136\/ard.2008.093179","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients","volume":"68","author":"Cervera","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD012169.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11926-009-0073-6","article-title":"Update on the diagnosis, treatment, and prognosis of the catastrophic antiphospholipid syndrome","volume":"12","author":"Cervera","year":"2010","journal-title":"Current Rheumatology Reports"},{"issue":"2","key":"10.1002\/14651858.CD012169.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000352060","article-title":"Risk prediction of subsequent early stroke in patients with transient ischemic attacks","volume":"36","author":"Chatzikonstantinou","year":"2013","journal-title":"Cerebrovascular Diseases"},{"issue":"12","key":"10.1002\/14651858.CD012169.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1177\/0961203314540968","article-title":"New oral anticoagulants in thrombotic antiphospholipid syndrome","volume":"23","author":"Chighizola","year":"2014","journal-title":"Lupus"},{"key":"10.1002\/14651858.CD012169.pub2-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"ID: 951424","DOI":"10.1155\/2015\/951424","article-title":"Treatment of thrombotic antiphospholipid syndrome: the rationale of current management - an insight into future approaches","volume":"2015","author":"Chighizola","year":"2015","journal-title":"Journal of Immunology Research"},{"key":"10.1002\/14651858.CD012169.pub2-BIB0052|cit52","unstructured":"Veritas Health Innovation Covidence"},{"issue":"2","key":"10.1002\/14651858.CD012169.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.rbre.2014.08.015","article-title":"Intensity of anticoagulation in the treatment of thrombosis in the antiphospholipid syndrome: a meta-analysis","volume":"55","author":"Silva","year":"2015","journal-title":"Revista Brasileira de Reumatologia (English Edition)"},{"issue":"2","key":"10.1002\/14651858.CD012169.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S2255-5021(13)70021-X","article-title":"Guidelines for the treatment of antiphospholipid syndrome","volume":"53","author":"Danowski","year":"2013","journal-title":"Revista Brasileira de Reumatologia (English Edition)"},{"issue":"3","key":"10.1002\/14651858.CD012169.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"12","key":"10.1002\/14651858.CD012169.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11926-016-0623-7","article-title":"Direct oral anticoagulants use in antiphospholipid syndrome: are these drugs an effective and safe alternative to warfarin? A systematic review of the literature","volume":"18","author":"Dufrost","year":"2016","journal-title":"Current Rheumatology Reports"},{"issue":"6","key":"10.1002\/14651858.CD012169.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1161\/STROKEAHA.108.192218","article-title":"Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association\/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease","volume":"40","author":"Easton","year":"2009","journal-title":"Stroke"},{"issue":"2","key":"10.1002\/14651858.CD012169.pub2-BIB0058|cit58","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002859.pub2","article-title":"Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant","author":"Empson","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD012169.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1002\/art.22663","article-title":"A randomized double blind placebo controlled trial in asymptomatic antiphospholipid antibody patients","volume":"56","author":"Erkan","year":"2007","journal-title":"Arthritis & Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD012169.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"685-96","DOI":"10.1016\/j.autrev.2014.01.053","article-title":"14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends","volume":"13","author":"Erkan","year":"2014","journal-title":"Autoimmunity Reviews"},{"issue":"10","key":"10.1002\/14651858.CD012169.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/nrrheum.2015.88","article-title":"Current treatment of antiphospholipid syndrome: lights and shadows","volume":"11","author":"Espinosa","year":"2015","journal-title":"Nature Reviews Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD012169.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1538-7836.2005.01340.x","article-title":"A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)","volume":"3","author":"Finazzi","year":"2005","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"5","key":"10.1002\/14651858.CD012169.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2002-02-0441","article-title":"Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature","volume":"101","author":"Galli","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD012169.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"115-25","DOI":"10.1016\/j.pcad.2009.06.005","article-title":"Antiphospholipid syndrome","volume":"52","author":"George","year":"2009","journal-title":"Progress in Cardiovascular Diseases"},{"issue":"2","key":"10.1002\/14651858.CD012169.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1182\/blood-2006-04-001206","article-title":"Current concepts on the pathogenesis of the antiphospholipid syndrome","volume":"109","author":"Giannakopoulos","year":"2007","journal-title":"Blood"},{"issue":"11","key":"10.1002\/14651858.CD012169.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJMra1112830","article-title":"The pathogenesis of the antiphospholipid syndrome","volume":"368","author":"Giannakopoulos","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012169.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jaut.2014.01.006","article-title":"Diagnosis and classification of the antiphospholipid syndrome","volume":"48-49","author":"G\u00f3mez-Puerta","year":"2014","journal-title":"Journal of Autoimmunity"},{"key":"10.1002\/14651858.CD012169.pub2-BIB0068|cit68","unstructured":"McMaster University GRADEpro GDT: GRADEpro Guideline Development Tool 2015 (developed by Evidence Prime, Inc.). Available from gradepro.org"},{"issue":"1","key":"10.1002\/14651858.CD012169.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2307\/2530643","article-title":"Estimation of a common effect parameter from sparse follow-up data","volume":"41","author":"Greenland","year":"1985","journal-title":"Biometrics"},{"issue":"7","key":"10.1002\/14651858.CD012169.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.puhe.2015.05.014","article-title":"Quality of life (QoL) and International Normalized Ratio (INR) control of patients attending anticoagulation clinics","volume":"129","author":"Hasan","year":"2015","journal-title":"Public Health"},{"key":"10.1002\/14651858.CD012169.pub2-BIB0071|cit71","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"7","key":"10.1002\/14651858.CD012169.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1161\/hq0701.093686","article-title":"Mechanism of action and pharmacology of unfractionated heparin","volume":"21","author":"Hirsh","year":"2001","journal-title":"Arteriosclerosis, Thrombosis and Vascular Biology"},{"issue":"5","key":"10.1002\/14651858.CD012169.pub2-BIB0073|cit73","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012198","article-title":"Antiplatelet and anticoagulant agents for preventing recurrence of peripheral vascular thrombosis in patients with antiphospholipid syndrome","author":"Islam","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1-2","key":"10.1002\/14651858.CD012169.pub2-BIB0074|cit74","first-page":"19","article-title":"Identification of patients with triple antiphospholipid antibody positivity is platform and method independent","volume":"126","author":"Iwaniec","year":"2016","journal-title":"Polskie Archiwum Medycyny Wewnetrznej"},{"issue":"1","key":"10.1002\/14651858.CD012169.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2141.2012.09037.x","article-title":"Guidelines on the investigation and management of antiphospholipid syndrome","volume":"157","author":"Keeling","year":"2012","journal-title":"British Journal of Haematology"},{"issue":"9","key":"10.1002\/14651858.CD012169.pub2-BIB0076|cit76","first-page":"e765","article-title":"Recommended therapeutic INR range for patients with antiphospholipid syndrome on warfarin anticoagulation: is moderate-intensity (INR 2.0-3.0) or high-intensity (INR 3.1-4.0) better for reducing risk of recurrent thromboembolic events","volume":"8","author":"Kim","year":"2016","journal-title":"Cureus"},{"issue":"9","key":"10.1002\/14651858.CD012169.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1001\/jama.295.9.1050","article-title":"Management of antiphospholipid antibody syndrome - a systematic review","volume":"295","author":"Lim","year":"2006","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD012169.pub2-BIB0078|cit78","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"Journal of the National Cancer Institute"},{"issue":"2","key":"10.1002\/14651858.CD012169.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.thromres.2013.11.012","article-title":"Risk factors for arterial thrombosis in antiphospholipid syndrome","volume":"133","author":"Matyja-Bednarczyk","year":"2014","journal-title":"Thrombosis Research"},{"issue":"2","key":"10.1002\/14651858.CD012169.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD012169.pub2-BIB0081|cit81","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"issue":"3","key":"10.1002\/14651858.CD012169.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s11926-013-0405-4","article-title":"Management of recurrent thrombosis in antiphospholipid syndrome","volume":"16","author":"Nalli","year":"2014","journal-title":"Current Rheumatology Reports"},{"issue":"1","key":"10.1002\/14651858.CD012169.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11926-011-0223-5","article-title":"The management of stroke in antiphospholipid syndrome","volume":"14","author":"Panichpisal","year":"2012","journal-title":"Current Rheumatology Reports"},{"issue":"24","key":"10.1002\/14651858.CD012169.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012169.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"237-42","DOI":"10.1111\/j.1538-7836.2009.03674.x","article-title":"Clinical course of high-risk patients diagnosed with antiphospholipid syndrome","volume":"8","author":"Pengo","year":"2010","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"17","key":"10.1002\/14651858.CD012169.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1182\/blood-2011-03-340232","article-title":"Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study","volume":"118","author":"Pengo","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1002\/14651858.CD012169.pub2-BIB0087|cit87","first-page":"672","article-title":"Diagnosis and therapy of antiphospholipid syndrome","volume":"125","author":"Pengo","year":"2015","journal-title":"Polskie Archiwum Medycyny Wewnetrznej"},{"issue":"2","key":"10.1002\/14651858.CD012169.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"145-51","DOI":"10.1006\/jaut.2000.0409","article-title":"Epidemiology of the antiphospholipid antibody syndrome","volume":"15","author":"Petri","year":"2000","journal-title":"Journal of Autoimmunity"},{"issue":"7-8","key":"10.1002\/14651858.CD012169.pub2-BIB0089|cit89","first-page":"552","article-title":"Adverse events associated with the use of direct-acting oral anticoagulants in clinical practice: beyond bleeding complications","volume":"126","author":"Raschi","year":"2016","journal-title":"Polskie Archiwum Medycyny Wewnetrznej"},{"key":"10.1002\/14651858.CD012169.pub2-BIB0090|cit90","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"9751","key":"10.1002\/14651858.CD012169.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(10)60709-X","article-title":"Antiphospholipid syndrome","volume":"376","author":"Ruiz-Irastorza","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD012169.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"206-18","DOI":"10.1177\/0961203310395803","article-title":"Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies","volume":"20","author":"Ruiz-Irastorza","year":"2011","journal-title":"Lupus"},{"issue":"6","key":"10.1002\/14651858.CD012169.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.thromres.2015.10.029","article-title":"Recurrent thrombosis in antiphospholipid syndrome may be associated with cardiovascular risk factors and inflammatory response","volume":"136","author":"Saraiva Sda","year":"2015","journal-title":"Thrombosis Research"},{"issue":"4","key":"10.1002\/14651858.CD012169.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"1","key":"10.1002\/14651858.CD012169.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"4","key":"10.1002\/14651858.CD012169.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1365-2125.2011.03943.x","article-title":"Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy","volume":"72","author":"Warner","year":"2011","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"9","key":"10.1002\/14651858.CD012169.pub2-BIB0097|cit97","first-page":"688","article-title":"Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulants","volume":"126","author":"Weitz","year":"2016","journal-title":"Polskie Archiwum Medycyny Wewnetrznej"},{"issue":"4","key":"10.1002\/14651858.CD012169.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/j.1365-2125.2011.03999.x","article-title":"Anti-platelet therapy: ADP receptor antagonists","volume":"72","author":"Wijeyeratne","year":"2011","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"7","key":"10.1002\/14651858.CD012169.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F","article-title":"International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop","volume":"42","author":"Wilson","year":"1999","journal-title":"Arthritis and Rheumatism"},{"issue":"3","key":"10.1002\/14651858.CD012169.pub2-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1177\/1076029615615960","article-title":"Apixaban for the secondary prevention of thrombosis among patients with antiphospholipid syndrome: study rationale and design (ASTRO-APS)","volume":"22","author":"Woller","year":"2016","journal-title":"Clinical and Applied Thrombosis\/Hemostasis"},{"issue":"4","key":"10.1002\/14651858.CD012169.pub2-BIB0101|cit101","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012169","article-title":"Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome","author":"Bala","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd012169.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T00:00:00Z","timestamp":1602460800000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD012169.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T19:03:39Z","timestamp":1628535819000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD012169.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Stroke Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,10,2]]},"references-count":101,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012169.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,2]]}}}